1. POSSIBLE WORKING PAPER 2. 3. Committe's name 4. Tópico B: 5. **Pa:** United States of America, Swiss Confederation, United Mexican 6. States, The Kingdom of Sweden.(4) 7. 8. Signatories: United States of America. Swiss Confederation, Kingdom of 9. Sweden, United Mexican States, Republic of South Africa, State Of Japan, 10. The United Kingdom of Northern Ireland and Great Britain, the French 11. Republic, Republic of India, Russian Federation, the People's Republic of 12. China, Canada.(12) 14. **Solemnly recalling** its attachment to the universal principles of human rights, 15. affirmed in the Universal Declaration of Human Rights of 10 December 1948; 17. Having paid attention to the 5° Article of the Universal Declaration on the 18. Human Genome and Human Rights which calls for research protocols to be, 19. in addition, submitted for prior review in accordance with relevant national and 20. international research standards or guidelines; 21. 22. **Guided by** 8° Article which states that every individual shall have the right, 23. according to international and national law, to just reparation for any damage 24 sustained as a direct and determining result of an intervention affecting his or 25.her genome; 26. 27. Taking in consideration 10° Article that announces that no research or 28. research applications concerning the human genome, in the fields of biology, 29 genetics and medicine, should prevail over respect for the human rights, 30, fundamental freedoms and human dignity of individuals or, where applicable, 31. of groups of people; 32. 33. Emphasizing on Article 19 which proclaims that: (a) In the framework of 34. international cooperation with developing countries, states should seek to 35. encourage enabling measures; (i) assessment of the risks and benefits 36 pertaining to research on the human genome to be carried out and abuse to 37. be prevented; (ii) the capacity of developing countries to carry out research 38. on human biology and genetics, taking into consideration their specific 39. problems, to be developed and strengthened; (iii) developing countries to 40. benefit from the achievements of scientific and technological research so that 41. their use in favour of economic and social progress can be to the benefit of all; 42. (iv) the free exchange of scientific knowledge and information in the areas of 43. biology, genetics and medicine to be promoted. (b) Relevant international 44. organizations should support and promote the initiatives taken by states for 45. the above-mentioned purposes; 46. 47. **Taking into account** that interventions on the human genome should be 48. admitted only for preventive, diagnostic or therapeutic reasons and without

49. enacting modifications for descendants:

50.

- 51. Aware that human gene editing techniques are a useful tool for the treatment 52. of diseases and conditions which damage quality of life of people, the 53. Commission:
- 54. **Draws the attention** in the implementation of strict permission tracking which 55. will consist in giving the permission to investigate to the best postulant, so the 56. inquiry will be in the best hands to avoid failures; 57.
- 58. **Designates** that every action, regarding the studies should be first asked to 59. biomedical institutes and congresses and Human Rights of each delegation, 60. including private and public research labs;

61.

62. **Taking in consideration** the United Nations Human Rights Council, the 63. signatory countries agree to allow the Council to be incharge of overseeing 64 the fulfillment of Human Rights throughout the development and 65. Investigations on human genomes and artificial embryos, guaranteeing the 66. respect of the humans dignity at all times;

67.

68. Fully alarmed by the fact that there exists the possibility that these 69 regulations may not always be considered and/or applied, the UN Human 70. Rights Council has the power to sanction any government or industry that 71 does not respect IHL, Human Rights and the respective regulations.

72.

- 73. Recognizing sanctions such as removing permission to continue with any 74. further investigations and the possible removal of medical licenses. 75.
- 76. Recognizing that different nations may be focalizing on different aspects, and 77. not for genetic enhancements; i.e. aesthetic purposes; the Human Rights 78. Council only allows the appliance of these technologies for medical purposes. 79.
- 80. Calls for advocacy and outreach from lawyers, bioethicists and journalists 81. involved to make sure they understand and interact with the topic properly. 82.
- 83. Guided by a criteria of scientific based reasoning, considering the 84. NIH parameters, which are:
- 85. A) Analytic Validity; referring to how thorough the investigations are to predict 86. the presence or not of genetic element or a mutation.
- 87. B) Clinical Validity; referring to the possible risk of having or developing a 88. disease when changing a variable in the gene structure
- 89. C)Clinical Utility; refers to the overall effectiveness of diagnosis, treatment, 90. management and prevention of diseases to improve health outcomes;

91.

92. Resolves that the "14 day rule" shall be an international guideline on which to 93. rely for the study of human embryos; which states that no human embryo is 94. subject to study beyond two weeks, or past when the primitive streak forms, 95. whichever comes first, being so that investigations have been made i.e The 96.1984 Warnock Report, enshrining the rule from the fact that a primitive 97. Nervous system has not been developed yet;

98.

99. **Notes** that the encouragement of the promotion of information and 100. research about this new era of human biology, referring to the ethical, legal 101. and social controversies of this polemic subject; 102. 103. **Proclaims** that human gene editing techniques, such as CRISPR/Cas9, 104. are to be defended and promoted as tool for the treatment of diseases and 105. conditions which affect the quality of life of people; The proposals are a 106. general guideline to the nations involved, the banning or not of editing 107. genes of human embryos is subject to each governments rule, if a country 108. in the future decides to begin investing in these investigations, it will have 109. to follow these regulations; 110. 111. Further recommends that with help of the International Laboratory for 112. Human Genome Research of the National Autonomous University of 1134 Mexico to make a global research of the diseases that prevail the most of 114. each country to focus on a more specific research; 1/15. Guided by the criteria of who are the best scientists to continue and to 116. 117. lead the research should be decided by each delegation. 118. 119. **Calls** on the signatories to regulate nationally or domestically these 120. technologies to ensure that local opinion and customs are admitted to 121. continue with research, privileging human health before anything; 122/ 123. Reserves the right of all delegations to ban or limit human genome editing 124. constituted by the national legislative organism; 125. 126. Considers appropriate to enact guidelines for the regulation of stem cell. 127. research for developing countries who may need it. 128. 129. Contemplating human and animal cloning, as they do not enter the 130. criteria of medical purposes, are not allowed to be experimented with, 131. as it goes against the IHL. 132. 133. **Considers** that the importance of bioethics is the key for the sake of 134. humankind, following the principles in the Convention for the Protection of 135. Human Rights and Dignity of the Human Being with regard to the 136. Application of Biology and Medicine always looking forward in protect the 137. the Human species. 138. 139. **Trusts** that after the approval of the Secretary General Aurora 140. Hernández López and Sub Secretary General Edith Rábago López, all 141. points established and discussed must be fulfilled when they are 142. members of it.